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Abstract 
At present, we have no evidence that we are doing more good than harm detecting and 
subsequently treating Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum 
colonisations/infections. Consequently, routine testing and treatment of asymptomatic or 
symptomatic men and women for M. hominis, U. urealyticum, and U. parvum is not 
recommended. Asymptomatic carriage of these bacteria is common and the majority of 
individuals do not develop disease. Although U. urealyticum has been associated with urethritis 
in men, it is probably not causal unless a high load is present (likely carriage in 40-80% of 
detected cases). The extensive testing, detection and subsequent antimicrobial treatment of 
these bacteria performed in some settings may result in selection of antimicrobial resistance, in 
these bacteria, “true” STI agents, as well as in the general microbiota, and substantial economic 
cost for society and individuals, particularly women. The commercialisation of many 
particularly multiplex PCR assays detecting traditional non-viral STIs together with M. 
hominis, U. parvum and/or U. urealyticum have worsened this situation. Thus, routine screening 
of asymptomatic men and women or routine testing of symptomatic individuals for M. hominis, 
U. urealyticum, and U. parvum is not recommended. If testing of men with symptomatic 
urethritis is undertaken, traditional STI urethritis agents such as Neisseria gonorrhoeae, 
Chlamydia trachomatis, M. genitalium and, in settings where relevant, Trichomonas vaginalis 
should be excluded prior to U. urealyticum testing and quantitative species-specific molecular 
diagnostic tests should be used. Only men with high U. urealyticum load should be considered 
for treatment, however, appropriate evidence for effective treatment regimens is lacking. In 
symptomatic women, bacterial vaginosis (BV) should always be tested for and treated if 
detected. 
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Introduction  
Mycoplasmas and ureaplasmas belong to the class Mollicutes. Mycoplasma genitalium is a 
“true” STI causing male urethritis, and is associated with cervicitis and an increased risk of 
pelvic inﬂammatory disease (PID), endometritis and infertility.1,2 However, Mycoplasma 
hominis, Ureaplasma urealyticum (previously U. urealyticum biovar 2) and U. parvum (earlier 
U. urealyticum biovar 1)3 are frequently found in the human urogenital tract in both healthy 
individuals and symptomatic patients.4 Comprehensive testing and subsequent antimicrobial 
treatment of these three urogenital mycoplasma species in adults is performed in several settings 
in, e.g., Eastern Europe, Southern Europe, South America and Asia. In many countries, this 
testing has also increased due the introduction of multiplex PCR assays detecting traditional 
non-viral “true” STI agents together with M. hominis, U. parvum and/or U. urealyticum,5-7 
These multiplex PCR assays can additionally have suboptimal specificity and/or sensitivity, 
particularly when home-sampled and self-sampled specimens, e.g. using sampling kit 
purchased on internet, are analysed. Nevertheless, the evidence base for these three 
mycoplasmas as aetiological agents of STI syndromes and complications in adult men and 
women can be questioned. Most older studies used culture and this is still commonly used due 
to the availability of simple and easy to use culture kits with inappropriate antimicrobial 
susceptibility testing. However, culture does not distinguish between U. urealyticum and U. 
parvum, and results are often reported as U. urealyticum instead of Ureaplasma spp. leading to 
further confusion. Qualitative PCR assays are also commonly used without species 
differentiation and with inappropriate reporting. Furthermore, in most studies, the strong 
association between bacterial vaginosis (BV) in “patient” and/or BV-associated bacteria in 
sexual partner of women with BV has not been adjusted for. This is particularly an issue for M. 
hominis but also for ureaplasmas.4,8-10 These and additional confounding factors make 
interpretation of many previous studies exceedingly difficult.  
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We reviewed the evidence for M. hominis, U. parvum and U. urealyticum as aetiological 
agents of urethritis, cervicitis and additional STI syndromes and complications in adult men 
and non-pregnant women. Based on current evidence, we conclude that routine testing and 
treatment of asymptomatic or symptomatic men and women for M. hominis, U. urealyticum, 
and U. parvum is not recommended. Furthermore, we suggest further research, and design of 
appropriate research studies, crucial to provide adequate evidence for any unresolved questions. 
To avoid some of the confounding factors, we focused on international peer-reviewed papers 
using molecular diagnostics and appropriate species differentiation. Relevance of these bacteria 
in pregnancy or in neonates was not addressed, because this has been reviewed recently 
elsewhere.11-15   
 
Men 
Male urethritis 
There is no evidence from case control studies that M. hominis causes non-gonococcal urethritis 
(NGU).16-20 It appears to be a relatively uncommon microorganism in men attending 
departments of sexual health (2-4%), although colonisation can be as high as 20%.16-18,21  
U. urealyticum and U. parvum can both be detected in men with and without NGU. Earlier 
studies did not differentiate between U. urealyticum and U. parvum, which continues to be the 
case if culture alone is used.9,10 U. parvum is detected more often in controls than cases in most 
studies, which probably explains why earlier studies failed to demonstrate a consistent 
association of ureaplasmas with NGU.9,10  
The population prevalence of U. parvum in men is unknown but it is likely more common 
than U. urealyticum as it is detected more frequently in men without urethritis than U. 
urealyticum.9,22 A recent meta-analysis of case control studies demonstrated no association of 
U. parvum with NGU.9 This was also observed by Frølund et al,22 but not in a few other studies 
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of non-chlamydial NGU where U. parvum was associated with microscopy-confirmed non-
chlamydial NGU (≥5 polymorphonuclear leukocytes in urethral swab) and/or disease, in 
particular when present in high loads.21,23,24   
Additional large and well-designed studies using quantitative molecular detection of U. 
parvum with appropriate cut-off for high bacterial load and microscopy to evaluate 
inflammation (polymorphonuclear leukocytes) in men with symptomatic urethritis might be 
valuable.  
The population prevalence of U. urealyticum is unknown but is probably 5-15% in men aged 
16-44 years old,21,22,25,26 being more common in younger men and associated with a recent 
change in sexual partner.26,27 U. urealyticum is associated with NGU. However, although 
detected in 5-24% of men with NGU it is probably only causal in 3-11% of NGU cases, i.e. in 
40-80% of cases it is probably only carriage.9,21,22,25,28,29 A recent meta-analysis demonstrated 
a significant association with 18.3% of men with NGU and 13.7% of controls being U. 
urealyticum-positive with a pooled odds ratio (OR) of 1.57 (95% CI: 1.05–2.35), p=0.029.9 
Although, NGU caused by U. urealyticum is more likely to develop in younger men, the 
majority of men carrying U. urealyticum will not develop NGU. The development of NGU is 
associated with a higher bacterial load and fewer lifetime sexual partners.22-24,30,31 As U. 
urealyticum carriage in men without urethritis is associated with younger age,26,27 this suggests 
that the adaptive immunity attenuates the clinical manifestation of U. urealyticum infection; 
repeated or prolonged exposure to U. urealyticum via multiple sex partners may result in either 
asymptomatic colonisation without signs of urethral inflammation or shorter duration of 
symptoms.22,27,31 Using quantitative molecular detection of U. urealyticum with appropriate 
cut-off for high bacterial load in men with symptomatic urethritis can significantly increase the 
positive predictive value.22,23,30,32 However, additional studies using different quantitative 
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molecular tests and examining symptomatic and asymptomatic male populations in different 
settings are required before any exact cut-off levels can be recommended.  
 
Male infertility 
A recent meta-analysis33 as well as two studies (which did not exclude “true” STIs or BV, and 
only included M. hominis culture positive samples)34,35 have suggested an association of M. 
hominis with infertility in men. However, M. hominis is strongly associated with several “true” 
STIs that can cause infertility as well as with BV,4,36 which is common in women, and two 
recent studies indicated that sexual partners share their genital tract microbiome, suggesting 
that molecular detection in men is likely to reflect the carriage in their female sexual partner.37,38 
BV is more common in women with infertility and is associated with tubal factor infertility as 
well as with poor implantation of the embryo as suggested by a study of women undergoing in 
vitro fertilisation (IVF).39,40 Thus, considerable caution should be exercised in attributing the 
detection of M. hominis as causal of male infertility before additional studies have been 
performed. These studies should be appropriately designed and use quantitative PCR, and 
address “true” STIs and BV as confounders (in infertile men and their sexual partners) as well 
as showing that treating the M. hominis infection in infertile men will restore fertility.    
A recent meta-analysis demonstrated no association with U. parvum but suggested an 
association between U. urealyticum and male infertility.33 Of the five included studies, three 
were from China where a high prevalence was observed in both cases (19.6%) and controls 
(8.3%)33 compared to a study from Jordan 1.1% vs. 2.9%41 and Iran 9% vs. 1%,42 respectively. 
Whether U. urealyticum actually causes male infertility remains unclear, some studies do not 
differentiate U. urealyticum and U. parvum, further complicating interpretation of the data.34,43-
45 Possible explanations for an inconsistent association in case control studies of male infertility 
include, failure to differentiate U. urealyticum and U. parvum44,45 and  association by 
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confounding as U. urealyticum is associated with younger age, recent change in sexual partner 
and fewer lifetime sexual partners and the association of ureaplasmas with BV.4,26,27,39  
 
Women 
The prevalence of M. hominis, U. urealyticum and U. parvum in non-pregnant sexually active 
symptomatic and asymptomatic women, measured by molecular tests including species 
differentiation, has ranged between 3.1-15%, 5.2-20%, and 20-89%, respectively.5,46-54 The 
large variation in prevalence probably reflect both methodological and true population 
differences, in particular in the prevalence of BV, the most important confounder. M. hominis 
and ureaplasmas can be horizontally transmitted and although colonization tends to decrease 
with age until puberty, detection of these bacteria in prepubertal girls even in the absence of 
sexual abuse is not unusual,55,56 which illustrates that sexual transmission is not required. 
Nevertheless, among adults most cases of new colonisation with M. hominis and ureaplasmas 
occurs from sexual contact57 and is correlated to the number of sexual partners.58  
Overall, in symptomatic women with dysuria, vaginal discharge, painful intercourse, and/or 
lower abdominal pain the spectrum of symptoms do not differ in ureaplasma-negative women 
compared to women positive for U. urealyticum or U. parvum.48 However, both of these 
ureaplasmas are frequently associated with increased positivity for several traditional STIs, e.g. 
C. trachomatis and M. genitalium, and/or BV.8,46,49,59 The bacterial load of particularly M. 
hominis and to a lesser extent U. parvum and U. urealyticum can be significantly increased in 
the dysbiosis of BV.4,48,60 However, despite the association between particularly M. hominis 
and BV, M. hominis cannot be detected in approximately one third of women with BV and, 
accordingly, it is neither a sufficiently sensitive nor specific bacterial marker for diagnosis of 
BV.8,61-63 Despite not being susceptible to metronidazole, eradication or a decrease in the M. 
hominis load after BV treatment has also been reported,64-66 further indicating that M. hominis 
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frequently belongs to the dysbiosis of BV. BV treatment studies using quantitative molecular 
detection methods for M. hominis, U. urealyticum and U. parvum are required. In many studies, 
appropriate species differentiation of U. urealyticum and U. parvum have not been performed 
and/or traditional STIs and especially BV have not been addressed as confounding factors, 
making disease association with the urogenital mycoplasmas exceedingly difficult.  
 
Vulvovaginitis 
There are no case control studies or other appropriate evidence that M. hominis, U. parvum or 
U. urealyticum causes an inflammatory vulvovaginitis.4,48,50 The number of leukocytes in 
vaginal smears are also not increased in women positive for only ureaplasmas.48   
 
Cervicitis  
No case control studies using sensitive and specific molecular diagnostic tests have provided 
appropriate evidence that M. hominis, U. parvum or U. urealyticum causes cervicitis. For 
example, the unadjusted prevalence ratios of cervicitis have been reported as 1.00, 1.09, and 
0.96 for M. hominis, U. parvum or U. urealyticum, respectively.67 Also in additional cervicitis 
studies, none of these three urogenital mycoplasmas was associated with cervicitis68 and the 
bacterial load of neither U. parvum nor U. urealyticum has been associated with symptoms or 
signs of genital infection.49 Nevertheless, in one molecular study of non-gonococcal non-
chlamydial cervicitis, despite no difference in U. parvum and U. urealyticum presence in 
women with cervicitis and controls69 the bacterial load of U. parvum and U. urealyticum were 
significantly higher in women with cervicitis compared to controls.69  
 
Female urethritis and urethral pain syndrome   
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Appropriate studies are mainly lacking, however, no case control or other studies providing 
evidence that M. hominis, U. parvum or U. urealyticum causes urethritis in women are 
available. One study of the urethral pain syndrome in women showed that 46% of women with 
urethral pain carried Ureaplasma species compared with 64% of the controls. The prevalence 
of U. parvum and U. urealyticum were similar in women with the urethral pain syndrome and 
controls.51 Using undifferentiated quantitative ureaplasma culture, early work suggested some 
evidence of a role of high bacterial loads in women with acute urethral syndrome.70 Studies 
using up-to-date quantitative techniques for ureaplasma detection are recommended.     
 
Pelvic Inflammatory Disease (PID), salpingitis and infertility 
Studies are few and no case control studies have yet provided appropriate evidence that M. 
hominis, U. parvum or U. urealyticum causes PID, salpingitis or infertility.71,72 Although M. 
hominis has been isolated from laparoscopically obtained samples, it was always found also in 
the vagina, so it may well be present in a background of BV-associated bacteria which were not 
cultured.73,74 In another study, the detection of M. hominis in the lower genital tract was not 
associated with C. trachomatis-negative and gonorrhoea-negative salpingitis and was not 
isolated from the salpinges indicating that it is unlikely to be causal.71 However, it is 
occasionally the sole pathogen isolated from the upper genital tract.74 In infertility, pooled data 
for non-pregnant women were analysed in a systematic review,52 and both M. hominis (11.5% 
vs. 14.5%, p=0.03) and U. urealyticum (19.5% vs. 25.0%, p=0.004) were more common among 
asymptomatic women presenting for infertility (n=1205) compared with symptomatic women 
(n=1131; with vulvovaginitis signs), possibly indicating an association with infertility. In 
general, C. trachomatis infection, gonorrhoea and/or BV as confounding factors have been 
present or not appropriately excluded in most studies, and BV is strongly associated with 
infertility.40 Microbiota studies of invasive samples in women with verified PID, e.g. 
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laparoscopically taken specimens, would be valuable to adequately address this as the BV 
associated bacteria are often uncultivable. 
 
Ectopic pregnancy 
There is no clear evidence that any of the urogenital mycoplasmas, including the “true” STI 
agent M. genitalium, result in ectopic pregnancy.75 
 
Discussion and conclusions 
In men, M. hominis does not cause disease and is probably mostly a reflection of BV in their 
sexual partner and the presence of U. parvum is not evidently associated with NGU or 
infertility.9,16-18,22 U. urealyticum is associated with a small proportion of NGU cases, in 
particular in younger men with fewer lifetime sexual partners and a high U. urealyticum load. 
However, in 40-80% of cases where it is detected, it is not the aetiological agent.9,21-23,25,28-32 
It remains unlikely that U. urealyticum can cause infertility.  
In women, there is no adequate evidence that M. hominis, U. parvum or U. urealyticum 
causes an inflammatory vulvovaginitis, cervicitis, urethritis, PID or infertility.4,48-51,67-
69,71,72,76,77 In many studies, appropriate species differentiation of U. urealyticum and U. parvum 
has not been performed and/or important confounding factors such as recognized STIs and 
especially BV have not been addressed, making disease associations with the urogenital 
mycoplasmas mostly undocumented.  
There are no international evidence-based management guidelines for M. hominis, U. 
parvum and U. urealyticum, and appropriate evidence for effective treatment regimens is 
lacking. Because mycoplasmas lack the rigid cell wall of other bacteria, they are intrinsically 
resistant to β-lactam antimicrobials, such as penicillins and cephalosporins, and other 
antimicrobials targeting the cell wall. M. hominis is additionally naturally resistant to 14- and 
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15-membered macrolides (azithromycin, clarithromycin, erythromycin), but not to 16-
membered macrolides such as josamycin and the in vitro susceptibility to doxycycline is high 
for strains lacking the tetM gene. U. urealyticum is moderately sensitive to 14-membered 
macrolides. In general, urogenital M. hominis, U. parvum and U. urealyticum can be difficult 
to eradicate in many individuals because of true antimicrobial resistance but also because of 
lower activity of the antimicrobials at low pH and lack of bactericidal activity.4,27,78-80 
Additionally, suboptimal antimicrobial susceptibility testing methods, including many 
commercial kits, are frequently used.80 The extensive treatment of these commonly colonising 
commensals with suboptimal antimicrobial regimens selects for antimicrobial resistance in 
these bacteria and in many of the more severe bacterial “true” STI agents as well as in the 
general microbiota. Overall, the extensive testing, detection (using microscopy, culture or PCR) 
and subsequent antimicrobial treatment of urogenital M. hominis, U. parvum and U. 
urealyticum in some settings result in a substantial burden and economic cost for society (e.g. 
unnecessary use of diagnostic tests, health care visits, antimicrobial misuse, and emergence of 
antimicrobial resistance) and individuals (e.g. economical burden, stigmatization, anxiety, and 
possibly breakdown of relationships including marriages). The commercialisation of many 
particularly multiplex PCR assays detecting traditional non-viral STIs together with M. 
hominis, U. parvum and/or U. urealyticum have worsened this situation. At present, we have 
no evidence that we are doing more good than harm detecting and subsequently treating these 
bacteria and increased awareness and education regarding all these issues among general 
population, laboratory staff, clinicians and other health care professionals is essential 
internationally. 
 
Should testing for M. hominis, U. urealyticum, and U. parvum be undertaken in STI 
syndromes?  
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• U. urealyticum in high bacterial loads might cause a small proportion of male NGU, but 
the majority of men and women infected/colonised with U. urealyticum do not develop 
disease. Antimicrobial treatment which results in eradication is difficult4,27,78,79 and cure 
is not associated with eradication.78 Treatment may result in development of 
antimicrobial resistance in urogenital mycoplasmas but also in other bacteria including 
the traditional, more severe “true” STI agents. Routine testing and/or treatment is 
therefore not recommended. If testing of men with symptomatic urethritis is undertaken, 
traditional STI urethritis agents such as N. gonorrhoeae, C. trachomatis, M. genitalium 
and, in settings where relevant, Trichomonas vaginalis should be excluded prior to U. 
urealyticum testing and quantitative molecular diagnostic tests should be used. Only 
men with high U. urealyticum load should be considered for treatment, however, 
appropriate evidence for effective treatment regimens is lacking.  
• Testing for M. hominis and U. parvum and subsequent antimicrobial treatment of 
positive men or women is currently not recommended. Instead, “true” STIs and BV in 
symptomatic women should be diagnosed and treated.  
Well-designed, large, randomised controlled studies to investigate unresolved issues regarding 
M. hominis, U. parvum and/or U. urealyticum and their independent associations with STI 
syndromes and complications such as possibly infertility,33-35 PID and prostate cancer81-84 could 
be valuable. In these studies, it is recommended to control age, sexual behaviour (number and 
change of sexual partners), use quantitative molecular diagnostic tests investigating bacterial 
load and microscopy to evaluate inflammation (polymorphonuclear leukocytes), distinguish U. 
urealyticum and U. parvum, and exclude traditional STIs such as gonorrhoea, chlamydia, M. 
genitalium and trichomoniasis. Furthermore, it is crucial to address aerobic vaginitis and 
particularly BV and ideally also the specific BV-associated bacteria in controls and 
symptomatic individuals positive for urogenital mycoplasmas and their sexual partners. It is 
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also important to show that antimicrobial treatment eradicates the mycoplasmas and that lack 
of eradication is associated with persistent symptoms and signs, documenting that it is not only 
an effect of treating a general dysbiosis.  
 
Key messages 
• Routine screening of asymptomatic men and women or routine testing of 
symptomatic individuals for Mycoplasma hominis, Ureaplasma urealyticum, and 
Ureaplasma parvum is not recommended.  
• The extensive testing, detection and antimicrobial treatment of urogenital M. hominis, 
U. parvum and U. urealyticum performed in some settings result in a substantial 
burden and economic cost for society and individuals, particularly women. Instead, 
the diagnostics and treatment of traditional, more severe “true” STIs and BV in 
symptomatic women need to be improved. 
• U. urealyticum in high bacterial loads might cause a small proportion of male NGU, 
but the majority of men and women infected/colonised with U. urealyticum do not 
develop disease. Antimicrobial treatment resulting in eradication is difficult, 
eradication is not strongly associated with cure, and treatment may select/induce 
resistance in urogenital mycoplasmas and other bacteria including the more severe 
“true” STI agents.  
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